2024³â Á¦39ȸ ´ëÇÑ°£ÇÐȸ Ãá°è Single Topic Symposium : 2024-03-16
±³À°ÀÏÀÚ : 2024-03-16
±³À°Àå¼Ò : ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ)
±³À°ÁÖÁ¦ : 2024³â Á¦39ȸ ´ëÇÑ°£ÇÐȸ Ãá°è Single Topic Symposium
ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
´ã´çÀÚ : ´ëÇÑ°£ÇÐȸ
¿¬¶ôó : 02-703-0051
À̸ÞÀÏ : kasl@kams.or.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 200¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª : ±¤ÁÖ±¤¿ª½Ã
±³À°½Ã°£ : 5 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í "»çÀüµî·Ï ȸ¿ø, ÀüÀÓÀÇ, Àü°øÀÇ 30,000¿ø ºñȸ¿ø, ¿Â¶óÀΠȸ¿ø 40,000¿ø
ÇöÀåµî·Ï ȸ¿ø, ÀüÀÓÀÇ, Àü°øÀÇ 40,000¿ø ºñȸ¿ø, ¿Â¶óÀΠȸ¿ø 50,000¿ø
¿Â¶óÀÎ Âü¿© ¹«·á"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 10:10~10:30 Mechanisms of Metabolic Dysfunction and Disease Consequences of MASLD(NAFLD) ¼Õ¿ø(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 10:30~10:50 Impact of Metabolic Risk Factors on Prognosis in Patients with Chronic Viral Hepatitis À±ÀçÇö(Àü³²ÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 10:50~11:10 Guidance for Surveillance and Diagnosis of HCC in Patients with MASLD(NAFLD) °û±Ý¿¬(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 11:10~11:30 Recent Advances in Lean MASLD(NAFLD) and Sarcopenia À¯Á¤È¯(ÀÎÇÏÀÇ´ë)
Åä·Ð 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 11:30~11:50 Discussion ( )
±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 12:50~13:10 Lifestyle Modifications in Obese and Lean Patients with MASLD(NAFLD): Different Way? ±èÁÖ¿µ(¹ÙÀÌ¿À´ºÆ®¸®¿Â)
±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 13:10~13:30 Endocrinologic Practice for Diabetes, Osteoporosis, and Obesity in Chronic Liver Disease ±èÁøÈ(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 13:30~13:50 Cardiovascular Practice for Dyslipidemia, Hypertension, and Atherosclerosis in Chronic Liver Disease Á¶°æÈÆ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 13:50~14:10 Specific Issues and Concerns in the Management of MASLD(NAFLD)-Related HCC Á¶ÁÖ¿¬(Á¶¼±ÀÇ´ë)
Åä·Ð 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 14:10~14:30 Discussion ( )
±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 14:50~15:10 Introduction and Implications of New NAFLD Nomenclatures: MAFLD vs. MASLD À±¾ÆÀϸ°(ÇѾçÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 15:10~15:30 Noninvasive Evaluation of MASLD(NAFLD) and Liver Fibrosis: Clinically Applicable? ÀÌâÈÆ(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 15:30~15:50 Molecular Basis and Mechanisms of Progression of MASH(NASH) ÇÑ¿ëÇö(°¿ø¾à´ë)
±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 15:50~16:10 Current and Emerging Pharmacological Options for MASH(NASH) and Obesity À̽¿ø(°¡Å縯ÀÇ´ë)
Åä·Ð 03¿ù 16ÀÏ 16:10~16:30 Discussion ( )